AC
CDAK

Armistice Capital’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Armistice Capital’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,000,000
Closed -$782K – 253
2022
Q3 		$782K Buy
+1,000,000
New +$2.1M 0.01% 144

Other funds holding CDAK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $863M AUM 30.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Armistice Capital's CDAK Position: Q4 2022 in Review

Armistice Capital sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q4 2022, closing a stake of 1,000,000 shares — an estimated $782K sold.

Armistice Capital first reported a position in CDAK in Q3 2022 and held it in 1 quarter. The position peaked at $782K in Q3 2022. 40 funds tracked by Wall St. Rank hold CDAK as of Q4 2022.

  • Armistice Capital reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Armistice Capital sold 1,000,000 Codiak BioSciences, Inc. Common Stock shares in Q4 2022, an estimated $782K.
  • Armistice Capital first reported a position in Codiak BioSciences, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Armistice Capital's Codiak BioSciences, Inc. Common Stock position peaked at $782K in Q3 2022.
  • 40 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q4 2022.

Based on Armistice Capital's 13F filing for Q4 2022, filed 14 Feb 2023.